Opinion
Video
A comprehensive discussion of the HIMALAYA study, evaluating the STRIDE regimen of durvalumab plus tremelimumab in first-line treatment for advanced HCC.
Zanidatamab Demonstrates Activity in Pretreated HER2+ Biliary Tract Cancer
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
EMA Validates Application for Nivolumab Plus Ipilimumab in Frontline HCC
D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
RMC-6236 Shows Activity With Favorable Toxicity Profile in Previously Treated PDAC
Innovative Research Continues to Propel Individualized GIST Treatments
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC